This project is so easy, AND fun. Plus you don’t need much.
What you will need:
Paper (any kind will work)
Markers (again, any kind at all) – Or just something to draw with. Crayons, colored pencils, or just a black sharpie!
…and that’s it! (we promise)
Watch this here:
Funding for this project was provided by the HealtheVoices Impact Fund at the Community Foundation of New Jersey, which was funded by a contribution from Janssen Pharmaceuticals, Inc.
Would you like your art featured in the AnCan Art Gallery? please email me at alexa (at) ancan.org!
To SIGN UP for any of our AnCan Virtual Support groups, visit our Contact Us page.
Hi-Risk/Recurrent/Advanced PCa Video Chat, June 20, 2022
Register for our upcoming webinar on June 29 on Genetics & Genomics at https://bit.ly/3QiNvxS
If you’re a Vet, AnCan will be launching a new Vets Group to help navigate medical care. First meeting Thu, June 23, at 8.00 pm Eastern in https://www.gotomeet.me/AnswerCancer. Free and drop-in as always!
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Editor’s Pick: We bookend this Group Session recalling our dear buddy and LEGEND advocate, Jerry Deans, who died last week (rd)
Topics Discussed
Consider rechallenging germline BRCA with a PARP-I; Next Generation Sequencing options; RT v HT for BCR … when you’ve been radiated 3x already; Peter K’s a rare bird, says Dr. Antonarakis – time for pembro!; Provenge follows Pluvicto; get the FAMILY germline BRCA tested; rd updates us on therapeutic radionuclides; Gary P expreses gratitude on behalf of single men; BCR points to recent SSPORT protocol; Dr. E switches HT protocol for this gent – to make Burning Man an easier trip!
Chat Log (OMG – were you Gent’s quiet this week or what??)
AnCan – rick (to Everyone): 5:10 PM: jturner@flinceresearch.com
Hi-Risk/Recurrent/Advanced PCa Video Chat, June 14, 2022
Register for our upcoming webinar on June 29 on Genetics & Genomics at https://bit.ly/3QiNvxS
If you’re a Vet, AnCan will be launching a new Vets Group to help navigate medical care. First meeting Thu, June 23, at 8.00 pm Eastern in https://www.gotomeet.me/AnswerCancer. Free and drop-in as always!
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Editor’s Pick: Long term survival with metastatic PCa is this week’s recurring theme (rd)
Topics Discussed
Newbie joins us with Lynch Syndrome; anti-PD1 immuno side effects, MSI – and the swab test for sensitivity; darolutamide monotherapy; brain fog from HT; lung nodules ID’d as PCa; stable, long-trm survivor; supporting non-particpants; care partners extend survival; when’s the right time for Pluvicto?; BIG Pluvicto success
Chat Log
AnCan – rick (to Everyone): 3:09 PM: Peter – I spoke with Alexa today about saving the chat. Evidently it depends on how you join. She will provide an explanation and directions in all our future emails.
George Rovder Arlington VA (to Everyone): 3:41 PM: Thank you Jeff Marchi. I appreciate it and will check it out. George
Len Sierra (to Everyone): 3:49 PM: https://miradx.com/imudx-testing/ The Keytruda test: IMUDX swab test ImuDx Testing Populations Patients with any type of cancer who are being considered for anti-PD1 or anti-PDL1 therapy are eligible for testing. This test predicts the risk of developing immune related adverse events in response to anti-PD1 or anti-PDL1 treatment.
Herb Geller (to Everyone): 3:50 PM: Cardiac toxicity from checkpoing therapy can range from asymptomatic troponin-I elevations to conduction abnormalities of the heart and even fulminant myocarditis. Although rare, myocarditis is a potentially fatal adverse effect of ICI therapy.
George Rovder Arlington VA (to Everyone): 3:54 PM: Thank you all, friends, for the wisdom and kindness. I have to leave early this evening. I will watch the video to see and hear the rest of the discussion. George
Julian Morales – Houston (to Everyone): 3:58 PM: Have to leave, have a conflicting meeting at 6pm.
Ben Nathanson (to Everyone): 4:00 PM: @Richard – ODENZA: A French prospective, randomized, open-label, multicenter, cross-over phase II trial of preference between darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (CRPC) https://meetings.asco.org/abstracts-presentations/201628
Pat Martin (to Everyone): 4:00 PM: Thanks for the info and the links
George A Southiere Jr (to Everyone): 4:04 PM: very correct that most of us have been on multiple treatments that cause”brain fog”would be very difficult to discern. Be very skeptical of Pharmaceutical studies
John Antonucci (to Everyone): 4:08 PM: I just tried to find any paper on monotherapy androgen blockers and came up with zilch
Thomas Jacobsen – CO (to Everyone): 4:43 PM: Have to leave. Thank you everyone.
Russ Strehlow (to Everyone): 4:46 PM: I have to leave also. Thank you
George A Southiere Jr (to Everyone): 4:50 PM: Great meeting everyone, gotta go. Be well all
Richard Wassersug (to Everyone): 5:00 PM: Thank you all. Have to go.
Herb Geller (to Everyone): 5:00 PM: I gotta go as well. See you all next week.
David Muslin (to Everyone): 5:01 PM: Great meeting as always. See you men next Monday night.
AND – if you’re a Vet, watch this space. AnCan will be launching a new Vets Group to help navigate medical care. It is not exlclusively prostate cancer, so tell Vet friends. 4th Thursday starting June. If you want to sign up please write Group Leader Joe Gallo joeg@ancan.org.
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Editor’s Pick: Prostate Cancer can occur in the testes!! And plenty of Provenge(rd)
Topics Discussed– long session this week with 2 newbies and 12 folks needing time!
Recurrent PCa does not respond to intermittent cycles; confined recurrence of focally treated high risk PCa; keeping the cancer offguard; Provenge – 2nd time today and not the last; IHT starting; Dr. E prescribes Pluvicto; Trimix experience; darolutamide beter than enz; remembering Hawaian Bob Smith; peritoneal implants (lesions) return; testicualr PCa lesion; UCLA refunds PSMA cost; lo-dose abi with food; pros & cons of self-cathetering; when to move on from chemo; morning fatigue and adjusting darolutamide dose; Provenge tips – again/finally!
Stephen Saft (to Everyone): 6:34 PM: I am going to say goodnight. Thanks
Joe Gallo (to Everyone): 6:43 PM: Vets interested can send me an email or drop in. Joeg@ancan.org
John Birch (to Everyone): 6:58 PM: Need to sign off, appreciate the discusssions tonight.
Frank Fabish – Ohio (to Everyone): 7:04 PM: thanks guys allowing me to give an update. Can’t make it next Tuesday.
Pat Martin (to Everyone): 7:07 PM: I’ll catch you next Tuesday. Good meeting
Mike Yancey (to Everyone): 7:15 PM: Got an early morning, so need to drop before we complete tonite. Lots of good discussion.
Julian Morales – Houston (to Everyone): 7:26 PM: need to drop off – another great meeting, Glad to be able to relate my experience to this community. All the best to everyone!
On June 1st, we had the pleasure of world renowned Dr. Steven Kaplan speaking to our Active Surveillance Prostate Cancer virtual support group, in collaboration with ASPI, titled “It Ain’t Your Grandpa’s BPH – An ‘Urgent’ Issue“.
Dr. Kaplan is Director of the Men’s Wellness Program, Mount Sinai Health System and Professor, Icahn School of Medicine at Mount Sinai. He is an internationally renowned authority and one of the primary thought leaders in the study of benign diseases, the association of metabolic factors with voiding dysfunction, and female urology, with symptoms related to both benign prostate enlargement and bladder function.
Dr. Kaplan is a Diplomat of the American Board of Urology and a Fellow of the American College of Surgeons. He is an internationally recognized authority and one of the primary thought leaders in the study of benign diseases of the prostate, the association of metabolic factors and voiding dysfunction and female urology. He has over 1000 publications including 600 peer reviewed and 570 peer reviewed invited articles, and 90 book chapters and non – peered reviewed articles. His landmark study, published in JAMA in 2006, changed the way medications are used in the treatment of men with symptoms related to both benign prostate enlargement and bladder dysfunction.
You’ll hear about the latest advancements in BPH, how diet and sleep can impact your prostate (and overall) health, and more.
Watch here:
Special thanks to Pfizer and Bayer for sponsoring this presentation
We apologize for the inconvenience, but slides for this presentation are not available.
For information on our peer-led video chat PROSTATE CANCER VIRTUAL SUPPORT GROUPS, click here.
To SIGN UP for the Group or any other of our AnCan Virtual Support groups, visit our Contact Us page.
